It is estimated that only around 20% of patients with solid tumors currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers, creating an immune excluded environment. Neobe Therapeutics is a new start up developing innovative live biotherapeutic products to disrupt these constraints from within. By acting locally within the tumor, these products avoid systemic toxicities while enabling immune infiltration. We aim to generate a new class of live therapeutic products which alter the local environment of solid tumors from within, establishing a platform for future drug development. Neobe was spun out from a collaboration between Deep Science Ventures and CRUK and is based at Open Cell labs in west London.